Wellstat Therapeutics Corporation (rights to uridine triacetate) Overview

  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • Asset Purch.
  • Financing Rounds
  • 1

Wellstat Therapeutics Corporation (rights to uridine triacetate) General Information

Description

Distribution rights in the United States of uridine triacetate drug. The drug is used for treating patients at risk of serious toxicity following an overdose of 5-flourouracil.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Buildings and Property
Other Industries
Other Commercial Services
Acquirer
BTG
Primary Office
  • 930 Clopper Road
  • Gaithersburg, MD 20878
  • United States
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Wellstat Therapeutics Corporation (rights to uridine triacetate) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Wellstat Therapeutics Corporation (rights to uridine triacetate)‘s full profile, request access.

Request a free trial

Wellstat Therapeutics Corporation (rights to uridine triacetate) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Wellstat Therapeutics Corporation (rights to uridine triacetate)‘s full profile, request access.

Request a free trial